Sentences with word «decitabine»

In the laboratory, the research team replicated human colorectal cancer in pre-clinical experiments and used bioinformatics analysis to demonstrate that a low - dose of the chemotherapy drug decitabine targeted the cancer stem cells by inducing viral mimicry.

Atrial fibrillation is associated with hypermethylation in human left atrium, and treatment with decitabine reduces atrial tachyarrhythmias in spontaneously hypertensive rats.

Dr. De Carvalho says: «Another important implication of our finding is that since decitabine induces an anti-viral response, which is highly immunogenic, it may be useful to combine this agent with immune therapy to further advance personalized cancer medicine by boosting an individual's natural defenses to fight disease.

New findings published in the Proceedings of the National Academy of Sciences showed in lab studies that supplementing an epigenetic cancer drug called decitabine with vitamin C enhanced the drug's ability to impede cancer cell growth and trigger cellular self - destruction in cancer cell lines.

When the leaderless hives received decitabine in their nectar, the worker bees became much more likely to develop ovaries and lay eggs.

It is a continuation of previous research, published in 2011, that focused on the effect of decitabine on glioblastoma human cell cultures.

In vitro, Jurkat cells bearing the KMT2D V5486M or EP300 H1377R mutant were treated with different concentrations of chidamide and / or the hypomethylating agent decitabine for 48 h.

In a xenograft KMT2D - mutated T - lymphoma model, dual treatment with chidamide and decitabine significantly retarded tumor growth and induced cell apoptosis through modulation of the KMT2D / H3K4me axis.

«By treating glioblastoma cells with decitabine, we found that we can unmask targets on the tumor cell that can be recognized by killer T cells.

A study led by UCLA's Drs. Robert Prins and Linda Liau, both UCLA Jonsson Comprehensive Cancer Center members, looked at the impact of a combined treatment using a chemotherapy drug called decitabine and genetically modified immune cells or T cell immunotherapy.

Both in vitro and in vivo, the combination of decitabine and chidamide induced apoptosis of Jurkat cells bearing the KMT2D mutant.

Azacytidine and Decitabine induce gene - specific and non-random DNA demethylation in human cancer cell lines

Dr. Rassool says that a clinical trial is planned to test whether low doses of a DNMT inhibitor, decitabine, and an investigational PARP inhibitor, talazoparib, can be safely combined and whether this therapy shows efficacy for AML patients, especially those who can not receive intensive chemotherapy, whose leukemia is resistant to treatment, or who have experienced a relapse after treatment.

DMNT inhibitors, such as 5 - azacytidine and decitabine, boost the interactions of PARP inhibitors to block these proteins even further, causing cancer cell death, the researchers found.

To determine whether methylation changes were actually causing the difference in bee behavior, the scientists used the drug decitabine.

Decitabine is approved by the U.S. Food and Drug Administration to treat myelodysplastic syndromes and leukemia, and for use in clinical trials for several types of solid - tumour cancers including colorectal.

Glioblastoma cells do not naturally produce NY - ESO - 1, so the drug decitabine is given prior to injecting the NY - ESO - 1 targeting T cells in order to cause the tumor cells to express the NY - ESO - 1 target.

Decitabine is approved by the U.S. Food and Drug Administration (FDA) for treating all MDS subtypes, though it is used most commonly to treat higher - risk MDS.

A new study demonstrates that it is possible to vaccinate patients with MDS against a decitabine - induced antigen and that the level of induced expression is sufficient to trigger cytotoxicity in patient - derived vaccine - induced T cells.

(A) Venn diagram depicting the overlap between transcription factors bound by H3K4me3 ChIP - seq in the combination group, as compared to the chidamide (CHID)- treated group and the decitabine (DECI)- treated group in KMT2D V5486 - mutated Jurkat cells.

To determine KMT2D - H3K4me3 DNA binding targets, ChIP - seq was performed using H3K4me3 antibody in KMT2D V5486M mutated Jurkat cells treated with chidamide (5 μm) alone or in combination with decitabine (5 μm) for 48 h. Presentation of the data in a Venn diagram identified a significant non-overlapping portion of H3K4me3 binding promoters in the combination group, excluding 663 promoters overlapping with the chidamide group and 17 with the decitabine group (Figure 5A, B).

The drugs, azacitidine (AZA) and decitabine (DAC), are epigenetic - targeted drugs and work to correct cancer - causing alterations that modify DNA.

In addition to the above, Dr. Matsuzaki has been conducting preclinical assessment of drug efficacy such as IDO inhibitor, rapamycin or decitabine that have been used in clinical trials.

Dr. Chou has shown that the drug decitabine (DAC), a chemotherapy that is currently approved to treat a form of pre-cancerous leukemia, can induce the expression of NY - ESO - 1 in colorectal and other types of cancers.

Another methylation inhibitor, decitabine (Dacogen), is also approved for MDS.